Real-World Study on the Burden of Hidradenitis Suppurativa

StatusCompleted
PhaseNot specified
SponsorPeriPharm
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Completed without a posted recruiting period Show 5 more changesShow less
    • Primary completion date changed from estimate of Jun 2026 to Oct 1, 2026
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 2026 to Feb 20, 2026
    • Secondary endpoints: details revised at 2 of 2 entries
    • Eligibility criteria expanded, about 4 words
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Despite the significant impact of HS on patients' quality of life (QoL) and daily functioning, there remains limited real-world evidence describing the burden of this condition in Canada. HS is an under-recognized and often misdiagnosed condition, with a substantial psychological and physical burden on patients. Understanding the real-world experiences of individuals living with HS in Canada can help identify unmet needs and inform patient-centered care approaches.
Trial Details
NCT Number NCT07323303
Lead Sponsor PeriPharm
Conditions
(from sponsor)		 Hidradenitis Suppurativa (HS)
Related terms Hidradenitis Suppurativa
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov